Evidence map›Paper›PMID 38562167›Full record

ArticleFrontiers in oncology2024

The frequency of

Muhammad Muhammad, Maher Saifo, Majd Aljamali, Mousa Alali, Khaled M Ghanem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Muhammad MuhammadBASMA Pediatric Oncology Unit, Damascus, Syria.
Maher SaifoDepartment of Oncology, Albairouni University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria.
Majd AljamaliDepartment of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria.
Mousa AlaliDepartment of Oncology, Albairouni University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria.
Khaled M GhanemBASMA Pediatric Oncology Unit, Damascus, Syria.
Damascus University · SYAtomic Energy Commission of Syria · SY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Polymorphisms in Methods: This is a retrospective study that included children with ALL reaching at least 6 months of maintenance therapy. The Results: A total of 92 patients were enrolled. The majority of the patients in the study population were low-risk (63.04%), followed by intermediate-risk (25%), and high-risk (11.96%). There were 5 patients (5.4%) with Conclusion: Approximately 6.5% of the study population exhibited reduced NUDT15 activity. The mercaptopurine dose intensity was considerably low in

Indexed as

acute lymphoblastic leukemiagenotypemercaptopurineNUDT15pediatricpharmacogeneticsSyriatoxicity

Identifiers

PMID38562167
PMCPMC10982510
OpenAlexW4392922249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.